Clinical trials: Interstitial Lung Diseases
Interstitial Lung Diseases
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
This study is open to adults with fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). People can join the study if they have been diagnosed with this condition within the last 3 years and are…
- Trial name
- NCT07540988
- Testing
- Nerandomilast
- Where
- 164 sites in United States, Argentina and 18 more
- Volunteers
- 466 people
- Sponsor
- Boehringer Ingelheim
Interstitial Lung Disease With Systemic Sclerosis
Pelvic Floor Dysfunction in Pulmonary Systemic Sclerosis
Systemic sclerosis (SSc) is a heterogeneous multisystem disease characterized by vascular dysfunction, immune abnormalities, and progressive fibrosis of the skin and internal organs.
- Trial name
- NCT07817160
- Testing
- Pelvic Floor Health Knowledge Assessment, Pelvic Floor Dysfunction Assessment, Core Endurance Assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 37 people
- Sponsor
- Biruni University
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Fibrosing Interstitial Lung Disease
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
This study is open to children and adolescents aged 2 to 17 years with interstitial lung disease (ILD). Nerandomilast has just been approved in some countries to help adults with a lung condition called idiopathic pulmonary…
- Trial name
- NCT07366034
- Testing
- Nerandomilast
- Where
- 47 sites in United States, Argentina and 20 more
- Volunteers
- 35 people
- Sponsor
- Boehringer Ingelheim
Lung Diseases, Interstitial
Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease
This is a Phase I, pilot clinical trial designed to evaluate the safety and exploratory efficacy of nebulized diluted amniotic fluid, Matrix (HAF-Matrix) in adults with interstitial lung disease (ILD).
- Trial name
- HAF ILD (NCT07372989)
- Testing
- Matrix
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Maule Stem Cell Research Institute, Inc.
Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection
CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia
To assess the efficacy of administrating daily caspofungin aerosols versus placebo for seven days, in adjunction of conventional systemic antifungal therapy during curative treatment of Pneumocystis pneumonia, on the clinical…
- Conditions
- Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection, Pneumocystis Infections
- Trial name
- CaspoNEB (NCT06892951)
- Testing
- Caspofungin Acetate 50 MG, Physiologic saline
- Where
- 3 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Tours
Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary…
- Trial name
- MOMENTOUS (NCT06911632)
- Testing
- ECG-based AI Device - Results Returned to Investigator, Echocardiogram and Right Heart Catheterization, ECG-based AI Device - Results Not Returned to Investigator
- Where
- 40 sites in United States
- Volunteers
- 900 people
- Sponsor
- Tempus AI
Fibrotic Interstitial Lung Disease, IPF and PPF
Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring
The purpose of this interventional study is to identify which combination of remote monitoring devices (e.g. home spirometry, pulse oximetry, scale, ePROs) is the most feasible (as defined by adherence, retention, and data…
- Conditions
- Fibrotic Interstitial Lung Disease, IPF and PPF, Lung Fibrosis Interstitial
- Trial name
- RESPOND-ILD (NCT07673237)
- Testing
- Spirometer, Oximeter, Scale
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of California, San Francisco
Restrictive Lung Diseases
Effects of Inspiratory Muscle Training and Positive Expiratory Pressure on Mechanically Ventilated Restrictive Lung Disease Patients
Restrictive lung diseases (RLD) represent a significant cause of morbidity, often necessitating intensive interventions such as mechanical ventilation due to diminished lung compliance (LC) and reduced total lung capacity (TLC).
- Trial name
- NCT07867730
- Testing
- Inspiratory muscle training, Conventional Chest Physical Therapy
- Where
- 3 sites in Pakistan
- Volunteers
- 30 people
- Sponsor
- Foundation University Islamabad
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH).
- Trial name
- ROCSTAR (NCT07175038)
- Testing
- ROC-101
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AllRock Bio, Inc.
Interstitial Lung Disease
Gabapentin vs. Benzonatate vs. Standard of Care for Cough in ILD
Absence of a clear standard of care and approved drug for chronic cough, the commonest symptom in ILD, calls for further research in this area.
- Trial name
- GAZEBO-ILD (NCT07859839)
- Testing
- Gabapentin, Benzonatate 200 mg, Standard of care treatment for ILD
- Where
- India
- Volunteers
- 177 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial
Assessment of Continuous Measurement of Transcutaneous CO2 for Evaluation of Alveolar Dead Space During Exercise
The study aim is to monitor, during exercise tests carried out in various conditions, the alveolar dead space, by means of continuous transcutaneous measurement of Pt CO2, which would be used as a surrogate for arterial PaCO2.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial, Chronic Heart Failure, Pulmonary Arterial Hypertension
- Trial name
- TEASE (NCT03718780)
- Testing
- simultaneous determination of PaCO2 and PtCO2, Hyperventilation test, Exercise test
- Where
- 4 sites in France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Metropole Savoie
Acute Respiratory Disease, COPD Exacerbation Acute
Study of Hospitalised Patients With Acute Respiratory Conditions
The goal of this observational study is to learn about the short- and long-term outcomes of people admitted to hospital with an acute respiratory condition, including exacerbations of chronic lung disease, and to understand…
- Conditions
- Acute Respiratory Disease, COPD Exacerbation Acute, Asthma, Pneumonia
- Trial name
- CHESTY (NCT05095090)
- Where
- United Kingdom
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Cardiovascular Disease, Asthma
Effectiveness of Pollution Monitoring in Clinical Exercise Rehabilitation
The primary objective of EPIC-AIR is to evaluate the feasibility and potential effectiveness of integrating real-time air pollution monitoring into cardiac rehabilitation (CR) and pulmonary rehabilitation (PR) programmes via an…
- Conditions
- Cardiovascular Disease, Asthma, COPD, Interstitial Lung Disease Due to Systemic Disease
- Trial name
- EPIC-AIR (NCT07500948)
- Testing
- Progressive Walking Exercise Programme, Real-time air quality information and guidance
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Interstitial Lung Diseases
Home-based Pulmonary Rehabilitation in Interstitial Lung Disease
Pulmonary rehabilitation (PR) is a comprehensive, multidisciplinary intervention incorporating exercise training, education, and behavior change, shown to improve dyspnea, exercise capacity, and health-related quality of life…
- Trial name
- NCT07830602
- Testing
- Home-based pulmonary rehabilitation, Standard-of-care treatment
- Where
- India
- Volunteers
- 80 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Systemic Sclerosis, Scleroderma
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis.
- Trial name
- DAISY (NCT05925803)
- Testing
- Anifrolumab (blinded), Anifrolumab (unblinded, open label)
- Where
- 150 sites in United States, Austria and 21 more
- Volunteers
- 314 people
- Sponsor
- AstraZeneca
Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred, making it harder to breathe.
- Conditions
- Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
- Trial name
- NCT07201922
- Testing
- Nerandomilast
- Where
- 55 sites in United States, Argentina and 11 more
- Volunteers
- 80 people
- Sponsor
- Boehringer Ingelheim
Systemic Sclerosis With Lung Involvement, Systemic Sclerosis
Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
The goal of this pilot study is to assess the feasibility of a larger study on the efficacy of mycophenolate mofetil in people diagnosed with systemic sclerosis with mild lung involvement.
- Conditions
- Systemic Sclerosis With Lung Involvement, Systemic Sclerosis, Interstitial Lung Disease
- Trial name
- SSc-mILD (NCT05785065)
- Testing
- Mycophenolate Mofetil
- Where
- 3 sites in Canada
- Volunteers
- 35 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Pulmonary Hypertension, Interstitial Lung Disease
Aerobic Exercise in Patients With Pulmonary Hypertension
This study will determine if a rehabilitation exercise program can help people with pulmonary hypertension (PH) increase their physical activity.
- Trial name
- NCT00678821
- Testing
- Aerobic exercise
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Sjögren's Disease, Interstitial Lung Disease
Clinical Efficacy of Telitacicept in Sjögren's Disease With Interstitial Lung Disease
This study aims to evaluate the efficacy Telitacicept in patients with primary Sjögren's Disease with interstitial lung disease
- Trial name
- NCT07843381
- Testing
- Telitacicept 160mg, Conventional treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital